Polymorphisms in

Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherland...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2016-09, Vol.17 (14), p.1483-1490
Main Authors: Bins, Sander, Lenting, Anne, El Bouazzaoui, Samira, van Doorn, Leni, Oomen-de Hoop, Esther, Eskens, Ferry ALM, van Schaik, Ron HN, Mathijssen, Ron HJ
Format: Article
Language:English
Subjects:
drug transporters
hepatocellular carcinoma
pharmacogenetics
renal cell cancer
sorafenib
toxicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1490
container_issue 14
container_start_page 1483
container_title Pharmacogenomics
container_volume 17
creator Bins, Sander
Lenting, Anne
El Bouazzaoui, Samira
van Doorn, Leni
Oomen-de Hoop, Esther
Eskens, Ferry ALM
van Schaik, Ron HN
Mathijssen, Ron HJ
description Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for and . The (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients. Polymorphisms in and are associated with several different sorafenib side effects.
doi_str_mv 10.2217/pgs-2016-0063
format article
fullrecord <record><control><sourceid>futurescience</sourceid><recordid>TN_cdi_futurescience_futuremedicine_10_2217_pgs_2016_0063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_pgs_2016_0063</sourcerecordid><originalsourceid>FETCH-futurescience_futuremedicine_10_2217_pgs_2016_00633</originalsourceid><addsrcrecordid>eNpjYBA1NNAzMjI01y9IL9Y1MjA00zUwMDNmYuA0NDcx0bUwMDFiAbJNzIx0jUwMzTgYuIqLswwMjAzNTAw4GQQC8nMqc_OLCjIyi3OLFTLzeBhY0xJzilN5oTQ3g6Wba4izh25aaUlpUWpxcmZqXnJqPISXm5qSmZyZlxpvaBAPckI80AnxICfEg5xgTIleAGR7PUw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Polymorphisms in</title><source>PubMed</source><creator>Bins, Sander ; Lenting, Anne ; El Bouazzaoui, Samira ; van Doorn, Leni ; Oomen-de Hoop, Esther ; Eskens, Ferry ALM ; van Schaik, Ron HN ; Mathijssen, Ron HJ</creator><creatorcontrib>Bins, Sander ; Lenting, Anne ; El Bouazzaoui, Samira ; van Doorn, Leni ; Oomen-de Hoop, Esther ; Eskens, Ferry ALM ; van Schaik, Ron HN ; Mathijssen, Ron HJ</creatorcontrib><description>Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for and . The (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients. Polymorphisms in and are associated with several different sorafenib side effects.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs-2016-0063</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>drug transporters ; hepatocellular carcinoma ; pharmacogenetics ; renal cell cancer ; sorafenib ; toxicity</subject><ispartof>Pharmacogenomics, 2016-09, Vol.17 (14), p.1483-1490</ispartof><rights>Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Bins, Sander</creatorcontrib><creatorcontrib>Lenting, Anne</creatorcontrib><creatorcontrib>El Bouazzaoui, Samira</creatorcontrib><creatorcontrib>van Doorn, Leni</creatorcontrib><creatorcontrib>Oomen-de Hoop, Esther</creatorcontrib><creatorcontrib>Eskens, Ferry ALM</creatorcontrib><creatorcontrib>van Schaik, Ron HN</creatorcontrib><creatorcontrib>Mathijssen, Ron HJ</creatorcontrib><title>Polymorphisms in</title><title>Pharmacogenomics</title><description>Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for and . The (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients. Polymorphisms in and are associated with several different sorafenib side effects.</description><subject>drug transporters</subject><subject>hepatocellular carcinoma</subject><subject>pharmacogenetics</subject><subject>renal cell cancer</subject><subject>sorafenib</subject><subject>toxicity</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNpjYBA1NNAzMjI01y9IL9Y1MjA00zUwMDNmYuA0NDcx0bUwMDFiAbJNzIx0jUwMzTgYuIqLswwMjAzNTAw4GQQC8nMqc_OLCjIyi3OLFTLzeBhY0xJzilN5oTQ3g6Wba4izh25aaUlpUWpxcmZqXnJqPISXm5qSmZyZlxpvaBAPckI80AnxICfEg5xgTIleAGR7PUw</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Bins, Sander</creator><creator>Lenting, Anne</creator><creator>El Bouazzaoui, Samira</creator><creator>van Doorn, Leni</creator><creator>Oomen-de Hoop, Esther</creator><creator>Eskens, Ferry ALM</creator><creator>van Schaik, Ron HN</creator><creator>Mathijssen, Ron HJ</creator><general>Future Medicine Ltd</general><scope/></search><sort><creationdate>20160901</creationdate><title>Polymorphisms in</title><author>Bins, Sander ; Lenting, Anne ; El Bouazzaoui, Samira ; van Doorn, Leni ; Oomen-de Hoop, Esther ; Eskens, Ferry ALM ; van Schaik, Ron HN ; Mathijssen, Ron HJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-futurescience_futuremedicine_10_2217_pgs_2016_00633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>drug transporters</topic><topic>hepatocellular carcinoma</topic><topic>pharmacogenetics</topic><topic>renal cell cancer</topic><topic>sorafenib</topic><topic>toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bins, Sander</creatorcontrib><creatorcontrib>Lenting, Anne</creatorcontrib><creatorcontrib>El Bouazzaoui, Samira</creatorcontrib><creatorcontrib>van Doorn, Leni</creatorcontrib><creatorcontrib>Oomen-de Hoop, Esther</creatorcontrib><creatorcontrib>Eskens, Ferry ALM</creatorcontrib><creatorcontrib>van Schaik, Ron HN</creatorcontrib><creatorcontrib>Mathijssen, Ron HJ</creatorcontrib><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bins, Sander</au><au>Lenting, Anne</au><au>El Bouazzaoui, Samira</au><au>van Doorn, Leni</au><au>Oomen-de Hoop, Esther</au><au>Eskens, Ferry ALM</au><au>van Schaik, Ron HN</au><au>Mathijssen, Ron HJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polymorphisms in</atitle><jtitle>Pharmacogenomics</jtitle><date>2016-09-01</date><risdate>2016</risdate><volume>17</volume><issue>14</issue><spage>1483</spage><epage>1490</epage><pages>1483-1490</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for and . The (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients. Polymorphisms in and are associated with several different sorafenib side effects.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/pgs-2016-0063</doi></addata></record>
fulltext fulltext
identifier ISSN: 1462-2416
ispartof Pharmacogenomics, 2016-09, Vol.17 (14), p.1483-1490
issn 1462-2416
1744-8042
language eng
recordid cdi_futurescience_futuremedicine_10_2217_pgs_2016_0063
source PubMed
subjects drug transporters
hepatocellular carcinoma
pharmacogenetics
renal cell cancer
sorafenib
toxicity
title Polymorphisms in
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A30%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polymorphisms%20in&rft.jtitle=Pharmacogenomics&rft.au=Bins,%20Sander&rft.date=2016-09-01&rft.volume=17&rft.issue=14&rft.spage=1483&rft.epage=1490&rft.pages=1483-1490&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs-2016-0063&rft_dat=%3Cfuturescience%3E10_2217_pgs_2016_0063%3C/futurescience%3E%3Cgrp_id%3Ecdi_FETCH-futurescience_futuremedicine_10_2217_pgs_2016_00633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true